William Blair Reaffirms Outperform Rating for Alto Neuroscience (NYSE:ANRO)

William Blair reiterated their outperform rating on shares of Alto Neuroscience (NYSE:ANRO) in a report issued on Friday morning,RTT News reports. William Blair also issued estimates for Alto Neuroscience’s Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Trading Up 0.6 %

ANRO stock opened at $2.71 on Friday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 52-week low of $2.58 and a 52-week high of $18.35. The business has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $6.05.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. Equities analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Jennison Associates LLC boosted its stake in shares of Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after buying an additional 370,612 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Alto Neuroscience by 182.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock worth $2,139,000 after buying an additional 120,779 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Alto Neuroscience by 84.5% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock worth $753,000 after buying an additional 30,135 shares during the last quarter. FMR LLC boosted its stake in shares of Alto Neuroscience by 1.4% in the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after buying an additional 32,040 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.